Singapore Institute of Advanced Medicine Holdings Ltd. (SGX:9G2)
Singapore · Delayed Price · Currency is SGD 0.0290
+0.0020 (7.41%)
At close: Sep 11, 2026
SGXC:9G2 Income Statement
Financials in millions SGD. Fiscal year is July - June.
Millions SGD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 15.72 | 15.71 | 16.65 | 16.23 | 13.81 | |
Revenue Growth | 0.05% | -5.63% | 2.54% | 17.56% | 6.90% |
Cost of Revenue | 8.86 | 8.94 | 7.83 | 6.37 | 5.17 |
Gross Profit | 6.86 | 6.77 | 8.82 | 9.87 | 8.64 |
Selling, General & Admin | 10.26 | 11.4 | 11.47 | 11.95 | 11.56 |
Amortization of Goodwill & Intangibles | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
Other Operating Expenses | 5.49 | 5.13 | 5.62 | 5.97 | 5.14 |
Operating Expenses | 26.54 | 28.48 | 29.55 | 23.69 | 21.95 |
Operating Income | -19.69 | -21.7 | -20.73 | -13.83 | -13.32 |
Interest Expense | -4.12 | -2.91 | -11.22 | -2.25 | -1.03 |
Interest & Investment Income | 0.03 | 0.03 | 0.04 | 0.03 | 0.02 |
Currency Exchange Gain (Loss) | - | 0.02 | -0.01 | 0.02 | -0.43 |
Other Non Operating Income (Expenses) | 0.01 | -0.11 | -7.28 | -3 | -0.16 |
EBT Excluding Unusual Items | -23.78 | -24.68 | -39.2 | -19.03 | -14.92 |
Gain (Loss) on Sale of Assets | 0.07 | - | 0.01 | -0 | 0.44 |
Asset Writedown | -0.18 | -2.47 | - | - | - |
Other Unusual Items | - | 0.1 | 1.75 | 0.06 | - |
Pretax Income | -23.89 | -27.05 | -37.44 | -18.96 | -14.48 |
Earnings From Continuing Operations | -23.89 | -27.05 | -37.44 | -18.96 | -14.48 |
Earnings From Discontinued Operations | -0.01 | -0.01 | -0.01 | 0.89 | 2.05 |
Net Income | -23.9 | -27.05 | -37.45 | -18.07 | -12.43 |
Net Income to Common | -23.9 | -27.05 | -37.45 | -18.07 | -12.43 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 1,191 | 1,052 | 823 | 679 | 645 |
Shares Outstanding (Diluted) | 1,191 | 1,052 | 823 | 679 | 645 |
Shares Change | 13.22% | 27.90% | 21.15% | 5.25% | 21.04% |
EPS (Basic) | -0.02 | -0.03 | -0.05 | -0.03 | -0.02 |
EPS (Diluted) | -0.02 | -0.03 | -0.05 | -0.03 | -0.02 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -4.14 | -10.8 | -13.46 | -17.68 | -9.89 |
Free Cash Flow Per Share | -0.00 | -0.01 | -0.02 | -0.03 | -0.01 |
Gross Margin | 43.62% | 43.11% | 52.99% | 60.78% | 62.54% |
Operating Margin | -125.26% | -138.15% | -124.56% | -85.17% | -96.43% |
Profit Margin | -152.04% | -172.22% | -224.95% | -111.32% | -89.98% |
Free Cash Flow Margin | -26.31% | -68.74% | -80.88% | -108.89% | -71.66% |
EBITDA | -8.9 | -12.72 | -11.19 | -10.99 | -11.01 |
EBITDA Margin | -56.61% | -81.00% | -67.25% | -67.71% | -79.74% |
D&A For EBITDA | 10.79 | 8.98 | 9.54 | 2.83 | 2.31 |
EBIT | -19.69 | -21.7 | -20.73 | -13.83 | -13.32 |
EBIT Margin | -125.26% | -138.15% | -124.56% | -85.17% | -96.43% |
Advertising Expenses | - | 0.25 | 0.29 | 0.23 | - |